Effectiveness of Plasma Transfusions in Critical Care Patients
NCT ID: NCT00302965
Last Updated: 2008-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
70 participants
INTERVENTIONAL
2005-04-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients
NCT01143909
Pre-hospital ECMO or Conventional Resuscitation for Refractory Cardiac Arrest
NCT06177730
Restricted or Liberal Fluid for Haemodynamic Resuscitation in Sepsis
NCT05453565
Optimal VAsopressor titraTION Pilot Randomized Controlled Trial
NCT01800877
A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy
NCT03178578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Frozen Plasma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* INR \> 1.2
* Require FFP for active bleeding and/or prior to an invasive procedure
* Are able to provide consent or proxy consent
Exclusion Criteria
* Platelet count \< 50 x 109 /L and have NOT received subsequent platelet transfusion
* Consumptive coagulopathy (bleeding ≥ 3 sites and ↓ plts, ↓ fib, ↑ d dimer)
* Uncontrolled bleeding (6 or more units of blood in the last 6 hours)
* Receiving therapeutic doses of heparin/heparinoid (must be off for at least 6 hours)
* Have received clotting factor concentrates in the previous 24 hours
* Are expected to require surgery in the next 48 hours
* Survival expected to be less than 48 hours
* Currently enrolled in another study with a similar outcome
* Previous enrollment in this study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ottawa Hospital Research Institute
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Tinmouth, MD
Role: PRINCIPAL_INVESTIGATOR
OHRI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ottawa Hospital
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004341-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.